EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery

Luis V Herrera-Marcos iD, Jose M Arbones-Mainar iD, Jesús Osada iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25158285 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Luis V Herrera-Marcos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Veterinaria, Universidad de Zaragoza, E-50013 Zaragoza, Spain. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Biomarkers, Lipidomics. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación-Fondo Europeo de Desarrollo Regional, Fondo Social Europeo-Gobierno de Aragón.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease characterized by the build-up of fat in the liver of individuals in the absence of alcohol consumption. This condition has become a burden in modern societies aggravated by the lack of appropriate predictive biomarkers (other than liver biopsy). To better understand this disease and to find appropriate biomarkers, a new technology has emerged in the last two decades with the ability to explore the unmapped role of lipids in this disease: lipidomics. This technology, based on the combination of chromatography and mass spectrometry, has been extensively used to explore the lipid metabolism of NAFLD. In this review, we aim to summarize the knowledge gained through lipidomics assays exploring tissues, plasma, and lipoproteins from individuals with NAFLD. Our goal is to identify common features and active pathways that could facilitate the finding of a reliable biomarker from this field. The most frequent observation was a variable decrease (1–9%) in polyunsaturated fatty acids in phospholipids and non-esterified fatty acids in NAFLD patients, both in plasma and liver. Additionally, a reduction in phosphatidylcholines is a common feature in the liver. Due to the scarcity of studies, further research is needed to properly detect lipoprotein, plasma, and tissue lipid signatures of NAFLD etiologies, and NAFLD subtypes, and to define the relevance of this technology in disease management strategies in the push toward personalized medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseBiomarkersLipidomicsHumansLipoproteinsLipid MetabolismLiverAnimals

Stichwörter der Autor:innen

NAFLDNASHbiomarkerslipidomiclipoproteinsliver

Substanzen

BiomarkersLipoproteins

Autor:innen und Institutionen

  • Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Veterinaria, Universidad de Zaragoza, E-50013 Zaragoza, Spain.
  • Instituto Agroalimentario de Aragón, CITA-Universidad de Zaragoza, E-50013 Zaragoza, Spain.
  • Instituto de Investigación Sanitaria (IIS) Aragon, E-50009 Zaragoza, Spain.
  • CIBER Fisiopatología Obesidad y Nutrición (CIBERObn), Instituto Salud Carlos III, E-28029 Madrid, Spain.
  • Adipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, E-50013 Zaragoza, Spain.
  • Instituto Aragonés de Ciencias de la Salud (IACS), E-50009 Zaragoza, Spain.

ORCID-Profile: Luis V Herrera-Marcos, Jose M Arbones-Mainar, Jesús Osada

Förderung

  • Instituto de Salud Carlos III
  • Ministerio de Ciencia e Innovación-Fondo Europeo de Desarrollo Regional
  • Fondo Social Europeo-Gobierno de Aragón
  • CIBER de Fisiopatología de la Obesidad y Nutrición
  • Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional “ERDF

Zitieren

APA

Herrera-Marcos, L. V., Arbones-Mainar, J. M., & Osada, J. (2024). Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158285

Vancouver

Herrera-Marcos LV, Arbones-Mainar JM, Osada J. Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158285

BibTeX
@article{HerreraMarcos2024,
  author = {Herrera-Marcos, Luis V and Arbones-Mainar, Jose M and Osada, Jesús},
  title = {Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25158285}
}
Kostenlos starten →